Aveo Capital Partners’s Novavax NVAX Stock Holding History

Aveo Capital Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,000	Closed	-$463K	–	290
2022 Q2	$463K	Sell	9,000 -26,505	-75%	-$1.37M	0.08%	184
2022 Q1	$2.62M	Buy	+35,505	New	+$3.17M	0.46%	61

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Aveo Capital Partners's NVAX Position: Q3 2022 in Review

Aveo Capital Partners sold out of Novavax (NVAX) in Q3 2022, closing a stake of 9,000 shares — an estimated $463K sold.

Aveo Capital Partners first reported a position in NVAX in Q1 2022 and held it in 2 quarters. The position peaked at $2.62M in Q1 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Aveo Capital Partners reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Aveo Capital Partners sold 9,000 Novavax shares in Q3 2022, an estimated $463K.
Aveo Capital Partners first reported a position in Novavax in Q1 2022 and held it in 2 quarters.
Aveo Capital Partners's Novavax position peaked at $2.62M in Q1 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Aveo Capital Partners's 13F filing for Q3 2022, filed 9 Nov 2022.